Equities research analysts expect that AstraZeneca PLC (NASDAQ:AZN) will post earnings per share (EPS) of $0.53 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for AstraZeneca’s earnings, with estimates ranging from $0.48 to $0.58. AstraZeneca reported earnings of $0.48 per share in the same quarter last year, which would suggest a positive year over year growth rate of 10.4%. The business is scheduled to announce its next earnings results on Thursday, July 29th.

According to Zacks, analysts expect that AstraZeneca will report full year earnings of $2.61 per share for the current year, with EPS estimates ranging from $2.42 to $2.83. For the next financial year, analysts expect that the firm will report earnings of $3.37 per share, with EPS estimates ranging from $3.08 to $3.68. Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for AstraZeneca.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, April 29th. The company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.11. The firm had revenue of $7.32 billion for the quarter, compared to analysts’ expectations of $7.15 billion. AstraZeneca had a return on equity of 37.23% and a net margin of 9.65%. AstraZeneca’s quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.05 EPS.

Several equities research analysts recently commented on the stock. Berenberg Bank reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Tuesday, March 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Thursday, March 18th. Societe Generale reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Tuesday, March 23rd. Jefferies Financial Group raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Monday, March 22nd. Finally, SVB Leerink lowered their price target on shares of AstraZeneca from $64.00 to $63.00 and set an “outperform” rating on the stock in a research note on Monday, March 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $83.40.

AstraZeneca stock traded down $0.58 on Thursday, reaching $53.12. 686,113 shares of the stock were exchanged, compared to its average volume of 10,960,672. AstraZeneca has a twelve month low of $46.48 and a twelve month high of $64.94. The company has a current ratio of 0.96, a quick ratio of 0.76 and a debt-to-equity ratio of 1.34. The stock has a market cap of $139.42 billion, a PE ratio of 55.24, a PEG ratio of 1.18 and a beta of 0.55. The firm has a fifty day moving average price of $50.52 and a two-hundred day moving average price of $50.87.

The company also recently announced a semi-annual dividend, which was paid on Monday, March 29th. Investors of record on Friday, February 26th were issued a dividend of $0.95 per share. This is an increase from AstraZeneca’s previous semi-annual dividend of $0.45. The ex-dividend date of this dividend was Thursday, February 25th. This represents a dividend yield of 2.7%. AstraZeneca’s payout ratio is 106.29%.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its position in shares of AstraZeneca by 18.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 18,596,691 shares of the company’s stock valued at $929,649,000 after purchasing an additional 2,946,561 shares during the period. Fisher Asset Management LLC lifted its stake in shares of AstraZeneca by 3.0% in the first quarter. Fisher Asset Management LLC now owns 18,388,688 shares of the company’s stock valued at $914,286,000 after buying an additional 537,914 shares during the period. BlackRock Inc. increased its holdings in shares of AstraZeneca by 73.7% during the fourth quarter. BlackRock Inc. now owns 12,062,631 shares of the company’s stock worth $603,010,000 after buying an additional 5,116,892 shares in the last quarter. Winslow Capital Management LLC boosted its stake in AstraZeneca by 9.0% in the fourth quarter. Winslow Capital Management LLC now owns 6,347,649 shares of the company’s stock valued at $317,318,000 after acquiring an additional 525,113 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in AstraZeneca by 4.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,537,677 shares of the company’s stock valued at $176,848,000 after buying an additional 149,386 shares during the last quarter. Institutional investors and hedge funds own 15.57% of the company’s stock.

About AstraZeneca

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.

Read More: EV Stocks

Get a free copy of the Zacks research report on AstraZeneca (AZN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.